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RETROSPECTIVE COMPARISON OF PHENYTOIN AND LEVETIRACETAM AS
SEIZURE PROPHYLAXIS WITH HIGH DOSE BUSULFAN DURING ALLOGE-
NEIC STEM CELL TRANSPLANT
Mathew, S.1, Harnicar, S.1, Adel, N.1, Papadopoulos, E.2 1Memorial
Sloan-Kettering Cancer Center, New York, NY; 2Memorial Sloan-
Kettering Cancer Center, New York, NY
Background: Busulfan is an alkylating agent commonly used in pre-
parative regimens for hematopoietic stem cell transplant (HSCT).
Early clinical trials, prior to the use of seizure prophylaxis, revealed
a high degree of neurotoxicity associated with myeloablative doses of
this agent. Phenytoin has been widely used as seizure prophylaxis
with busulfan. However, potential concerns with its use include
the length of time to achieve a therapeutic steady state, risk of hep-
atotoxicity, and drug-drug interactions with busulfan and other
agents used during conditioning. Alternatively, levetiracetam is
highly bioavailable in both oral and intravenous forms, with a short
half life it rapidly achieves steady state and is renally eliminated with
limited drug interactions. The main objective of this study was to
compare the incidence of seizures with phenytoin and levetiracetam.
Secondary objectives were to compare VOD incidence, assess busul-
fan and phenytoin pharmacokinetics, and toxicity of the prophylactic
agents.
Methods: All patients$ 18 years of age receiving busulfan in a pre-
parative regimen prior to HSCT between 6/1/08-6/30/09 were in-
cluded in this retrospective analysis. Patient information was
collected from the pharmacy database and electronic medical re-
cords. Data included age, disease, preparative regimen, type of trans-
plant, busulfan dose, busulfan AUC, survival status, incidence of
relapse, and hepatic panels.
Results: 54 patients were included in this analysis with 22 receiving
phenytoin and 32 receiving levetiracetam as seizure prophylaxis.
Phenytoin was dosed with a 1000 mg loading dose and 300 mg
daily maintenance dose. Levetiracetam was dosed at 500 mg twice
daily. Of the 54 patients there were no reports of seizures in either
group. There were also no reports of VOD in either group. Eleva-
tion in liver enzymes occurred in 3 (9%) patients who received lev-
etiracetam compared to 7 (32%) patients who received phenytoin.
A therapeutic steady state of phenytoin was achieved in 12 (55%)
patients. Twenty patients (63%) receiving levetiracetam needed bu-
sulfan dose adjustments based on pharmacokinetic analysis versus
11 (50%) receiving phenytoin. Rates of relapse were similar in
both groups.
Conclusion: Levetiracetam is a safe and effective alternative to phe-
nytoin for busulfan seizure prophylaxis. With low hepatoxicity, no
pharmacokinetic monitoring, and limited drug-drug interactions it
is an attractive option in the HSCT population.558
WEIGHT-BASED DOSING OF VALGANCICLOVIR IN PEDIATRIC HSCT RE-
CIPIENTS
Nguyen, N.-Y.1, Puebla, M.1, Krance, R.A.2 1Texas Children’s Hospital,
Houston, TX; 2Baylor College of Medicine, Houston, TX
Background: IV ganciclovir is the standard therapy to prevent CMV
infection in HSCT recipients at Texas Children’s Hospital. In 2001,
the FDA approved valganciclovir (VGC) for treatment of CMV ret-
initis in AIDS patients. This oral preparation increased the oral bio-
availability of ganciclovir from 5% to 60% and demonstrated a well
established safety profile. The oral route of administration avoids the
need for a central line and markedly decreases the added costs asso-
ciated with IV therapy. Unfortunately, data as to the efficacy of VGC
to preventCMV infection in pediatricHSCT recipients is limited. In
2004, our institution reported positive experience in liver transplant
patients using 15–18 mg/kg/dose. Encouraged by this result, the
HSCT program began using a similar dosing strategy for patients
unable to receive IV ganciclovir. This report evaluates the efficacyand safety of weight-based dosing of VGC for CMV prophylaxis
in pediatric HSCT recipients.
Methods: Thus far, we have evaluated thirty-two patients (2-20
years old) for this retrospective study. The inclusion criteria were: al-
logeneic HSCT recipients, CMV seropositive (donor and/or recip-
ient) prior to transplantation, received VGC $ 7 days. Exclusion
criteria were: ANC\ 500 and renal dysfunction. Efficacy was de-
fined as no incidence of CMV reactivation during therapy based
upon the development of CMV antigenemia or the presence of
CMV by quantitative PCR (qPCR). ANC served as a marker for
safety. The dosing was as follows: 15-18 mg/kg/dose (max 900 mg)
twice daily for 14 days, then once daily thereafter.
Results:Thedurationof therapy ranged 7days to2 years.The average
dose for patients\60 kgwas 15.2mg/kg/dose (8.2– 22.5mg/kg/dose.)
Patients$ 60 kg received a maximum 900 mg per dose. CMV reacti-
vationwas not observed in 30of 32 patients.Therapywas discontinued
in 4 patients due to declining ANC. Four patients required filgrastim
intermittently to maintain ANC. 500. Effect on ANC cannot be as-
sessed for one patient due to concurrent treatment with hydroxyurea.
Most importantly, no patient developed CMV pneumonitis.
Conclusion:Our data demonstrate that valganciclovir 15 – 18mg/kg/
dose is effective and safe as a CMV prophylactic regimen in pediatric
HSCT patients. However, frequent monitoring, including CMV
qPCR and hematologic profile, is necessary with VGC therapy.559
USE OF HEPATITIS B IMMUNE GLOBULIN AND ADEFOVIR IN A CORD
BLOOD TRANSPLANT RECIPIENT
DiMicco, M.G., Ahmed, T. Westchester Medical Center, Valhalla, NY
A 52-year old female with acute myelogenous leukemia in remis-
sion presented for a matched unrelated donor hematopoeitic stem
cell transplant, testing negative for Hepatitis B surface antigen.
The recipient underwent HPCT conditioning using the Slavin reg-
imen. The patient’s human leukocyte antigen (HLA) typingmatched
with a cord blood donation from a twin birth where the mother was
found to be Hepatitis B surface antigen positive; the HBsAg status of
the twin donors was unknown at the time of hematopoeitic stem cell
transplantation.
As a precaution against the recipient developing a Hepatitis B in-
fection, Hepatitis B Immune Globulin and Adefovir was adminis-
tered as chemoprophylaxis. Dosing of Hepatitis B Immune
Globulin was derived from the liver transplant literature. Hepatitis
B Immune Globulin 20,000 international units was given intrave-
nously on transplant day zero and repeated on transplant days 1
through 7. Additional doses were scheduled for every two weeks
to begin on transplant day +14. Adefovir 10 mg was ordered to
be administered by mouth daily beginning on transplant day nega-
tive 2.
On transplant day +19 the HBsAg status of the twin donors was
discovered to be negative.Hepatitis B chemoprophylaxis was discon-
tinued at that time with no additional doses administered to the re-
cipient.
Hepatitis B Immune Globulin is used in the liver transplantation
population to prevent hepatitis B virus recurrence inHBsAg-positive
recipients after transplantation. Adefovir is used to treat chronic hep-
atitis B infections.560
DECLINE IN BONE MINERAL DENSITY IN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: IMPACT OF MYELOABLATIVE VERSUS
REDUCED INTENSITY CONDITIONING REGIMENS
McCullough, K.B.1, Burzynski, J.A.1, Hogan, W.J.2, Litzow, M.R.2,
Wolf, R.C.1, Wermers, R.A.3 1Mayo Clinic, Rochester, MN; 2Mayo
Clinic, Rochester, MN; 3Mayo Clinic, Rochester, MN
Background:Comparedwithmyeloablative (MA) regimens, reduced
intensity conditioning (RIC) regimens have shown a lower incidence
of some complications (veno-occlusive disease, pre-engraftment in-
fections, bronchiolitis obliterans); however, the incidence is similar
for others (chronic kidney disease, hypothyroidism). The incidence
of osteoporosis and osteopenia has not been compared.
Table 1. Changes in Bone Mineral Density
Myeloablative Regimen N 5 30 Reduced Intensity Regimen N 5 20
Day 100 BMD Follow up BMD Change (%/year) Day 100 BMD Follow up BMD Change (%/year) p
BMD spine (g/cm2) 1.159 1.139 21.4% 1.024 1.031 0.8% 0.152
T score spine 20.4 20.6 21.5 21.5
Z score spine 20.3 20.5 21.2 21.2
BMD left hip (g/cm2) 1.009 0.962 24.5% 0.946 0.901 25.0% 0.850
T score left hip 20.4 20.7 20.9 21.3
Z score left hip 20.2 20.5 20.5 20.9
BMD right hip (g/cm2) 0.997 0.963 25.6% 0.936 0.900 25.5% 0.859
T score right hip 20.5 20.7 20.9 21.3
Z score right hip 20.2 20.5 20.6 20.9
BMD left femoral neck (g/cm2) 0.964 0.917 24.0% 0.905 0.853 26.7% 0.598
T score left femoral neck 20.7 21.0 21.2 21.6
Z score left femoral neck 20.3 20.6 20.4 20.9
BMD right femoral neck (g/cm2) 0.955 0.918 25.5% 0.912 0.865 26.7% 0.537
T score right femoral neck 20.7 21.0 21.2 21.5
Z score right femoral neck 20.3 20.6 20.4 20.8
Fracture incidence 0 3 0 0
Table 1. Patient Characteristics
n 5 46
Mean age (range) 48 (21-69)
Sex (%)
Male 30 (65)
Underlying diagnosis (%)
Acute myelogenous leukemia 20 (43.5)
S354 Poster Session IIMethods: IRB approval and patient consent were obtained prior to
review of electronic medical records and Mayo Clinic HSCT data-
base. Adult patients receiving an allogeneic HSCT from 1/1/2007
to 7/15/2010 with two dual-energy x-ray absorptiometry (DEXA)
scans were included. Patients were excluded if they refused research
consent; had a diagnosis of myelofibrosis or multiple myeloma, or no
DEXA scan within 30 days of day 100. Osteoporosis was defined as
a T score less than or equal to -2.5; osteopenia was defined as a T
score -2.4 to -1.5. Baseline demographics and risk factors known
to impact bone density were collected.
Results: From 1/1/2007 to 7/15/2010, 200 patients received an allo-
geneic HSCT; 74 were excluded: 29 myelofibrosis or multiple mye-
loma patients; 14 expired before day 100; 27 had no DEXA scan; 4
refused research consent. In 126 patients with a day 100 BMD,
25% had osteopenia, 17% had osteoporosis, and 12% had fractures.
Fifty patients had a day 100 and second DEXA scan: 30 MA and 20
RIC. The median age at transplant in RIC versus MA was 59 years
versus 45 years, respectively. Changes in BMD and fracture inci-
dence are reported in Table 1. Mean duration between day 100
and second DEXA was 0.92 years. Between day 100 and the second
DEXA,most patients (78%) received steroids and 22% received a bi-
sphosphonate.
Conclusions: There is no difference in BMD between day 100 and
follow-up in patients receiving MA versus RIC allogeneic HSCT.
Lack of observed difference may be due to age, pre-transplant
bone loss, or bisphosphonate use.Myelodysplastic syndrome 4 (9)
Acute lymphoblastic leukemia 1 (2)
Chronic myelogenous leukemia 6 (13)
Chronic lymphocytic leukemia 7 (15)
Lymphoma 4 (9)
Other malignancies 4 (9)
HLA matching (%)
Matched 40 (87)
1-antigen mismatch 5 (11)
2-antigen mismatch 1 (2)
Donor source (%)
Related 15 (33)
Unrelated 31 (67)
Stem cell type (%)
Peripheral blood 42 (91)
Bone marrow 4 (9)
CMV serostatus (%)
D+/R+ 8 (17)
D+/R- 6 (13)
D-/R+ 9 (20)
D-/R- 23 (50)
Conditioning regimen (%)
Bu/Cy 12 (26)
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A RETROSPECTIVE EVALUATION OF DACLIZUMAB FOR THE MANAGE-
MENT OF STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN
ADULTS
Hladnik, L.M.1, McBride, A.1, Augustin, K.M.1, Reichley, R.M.1,
Smith, A.2, Wartman, L.2, Pusic, I.2, DiPersio, J.F.2 1Barnes-Jewish
Hospital, Saint Louis, MO; 2Washington University School of Medicine,
Saint Louis, MO
Steroid-refractory graft-versus-host disease (GVHD) in alloge-
neic stem cell transplant patients carries a poor prognosis with lim-
ited options for effective therapy. Daclizumab, a humanized
monoclonal antibody to the alpha subunit of the interleukin-2 (IL-
2) receptor, has been used for the treatment of steroid-refractory
GVHD, with varied response rates noted in the literature. To
date, we have treated and retrospectively reviewed 44 adults who re-
ceived 46 courses of daclizumab for GVHD unresponsive to or pro-
gressing on corticosteroids between January 2006 and July 2009 at
our institution. Five doses of daclizumab (1 mg/kg) were adminis-
tered during a course of therapy on days 1, 4, 8, 15, and 22. Table
1 describes the patient characteristics. GVHD diagnosis was made
a median of 54.5 days (range 12 – 1247 days) and daclizumab was ini-tiated a median of 69 days (range 23 – 1276 days) after transplant.
Prior to daclizumab, patients had the following distribution of organ
involvement: 59% skin, 70% gastrointestinal (GI), and 43% liver,
with 72% of patients having multi-organ involvement. At baseline,
grades 1, 2, 3, and 4 GVHD (IBMTR grading system) were found
in 2%, 12%, 43%, and 43% of patients respectively. At day 28 of da-
clizumab, overall response rate was 28% with 14% of patients
achieving a complete response, 14% with a partial response, 9.5%
with stable disease, and 57% with GVHD progression. Overall sur-
vival at day 28 and 1 year after daclizumabwas 74% and 22%, respec-
tively. Fifteen percent of patients remain alive. Primary causes of
death include relapsed malignancy (15%), treatment-related mortal-
ity (63%), respiratory failure (2%), metastatic melanoma (2%), and
unknown causes (2%). Data evaluating the effect of daclizumab on
chronic liverGVHDwith bile duct dropout is limited, but this subset
